Keyphrases
Docetaxel
100%
Prednisone
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Progression-free Survival
28%
Abiraterone
21%
Corticosteroids
14%
Confidence Interval
14%
Ketoconazole
14%
Median Progression-free Survival
14%
Risk Reduction
7%
Tumor Response
7%
Disease Course
7%
Multivariable
7%
Patients with Prostate Cancer
7%
Consecutive Patients
7%
PSA Response
7%
Prednisone Therapy
7%
Cox Model
7%
Cox Regression Model
7%
Hydrocortisone
7%
Palliation
7%
Additional Treatment
7%
Cohort-based
7%
Propensity Score
7%
Multivariable Cox Regression
7%
Pretreated Patients
7%
PSA Progression
7%
Radiographic Progression-free Survival
7%
Risk of Progression
7%
First Treatment
7%
Pharmacology, Toxicology and Pharmaceutical Science
Docetaxel
100%
Castration Resistant Prostate Cancer
100%
Prednisone
100%
Progression Free Survival
46%
Abiraterone
20%
Ketoconazole
13%
Retrospective Study
6%
Prostate Cancer
6%
Disease Course
6%
Hydrocortisone
6%
Neoplasm
6%
Immunology and Microbiology
Prednisone
100%
Prostate
100%
Progression Free Survival
46%
Cortisol
6%